Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7881612 | 0.93 | CYP1A2 (0.42) | HSD17B10MEN1KMT2ACA1CA2 | |
| SCHEMBL6454577 | 0.86 | ALDH1A1 (0.38) | CA1CA2CA9LMNACYP2A6 | |
| SCHEMBL5049780 | 0.78 | ALDH1A1 (0.41) | HSD17B10MEN1KMT2ALMNAMAOA | |
| SCHEMBL17297207 | 0.78 | DRD1 (0.40) | HSD17B10CA1CA2CA9CYP2A6 | |
| SCHEMBL9809027 | 0.78 | ALDH1A1 (0.41) | HSD17B10MEN1KMT2ALMNAMAOA | |
| SCHEMBL96668 | 0.74 | ALDH1A1 (0.58) | CA1CA2CA9LMNACYP2A6 | |
| SCHEMBL535420 | 0.74 | LMNA (0.42) | HSD17B10MEN1KMT2ACA1CA2 | |
| SCHEMBL95902 | 0.74 | ACHE (0.48) | MEN1KMT2ACA1CA2CA9 | |
| SCHEMBL21515006 | 0.74 | ALDH1A1 (0.31) | CYP2A6ALDH1A1 | |
| SCHEMBL194685 | 0.74 | LMNA (0.42) | HSD17B10MEN1KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119371309-A | Indenoacetates method for synthesizing compound | 南通大学 | 2025-01-28 | — | — | CN | claimed |
| EP-2636669-B1 | PYRAZOLE AMIDE COMPOUND AND USE THEREOF AS FUNGICIDE | SINOCHEM CORP (CN) | 2015-10-21 | — | — | EP | claimed |
| CN-104177340-A | Novel quinazoline (sulfur) ketone compound and application | SINOCHEM CORP | 2014-12-03 | — | — | CN | claimed |
| EP-2636669-A1 | PYRAZOLE AMIDE COMPOUND AND USE THEREOF | Sinochem Corporation (CN) | 2013-09-11 | — | — | EP | claimed |
| US-20130225585-A1 | PYRAZOLE AMIDE COMPOUNDS AND USES THEREOF | SHENYANG RESEARCH INSTITUTE OF CHEMICAL INDUSTRY CO., LTD. (CN) | 2013-08-29 | — | — | US | claimed |
| CN-102453149-A | Olefin polymerization catalyst component, olefin polymerization catalyst, and olefin polymerization method | CHINA PETROLEUM & CHEMICAL | 2012-05-16 | — | — | CN | claimed |
| WO-2010128516-A2 | PROCESS FOR THE PREPARATION OF FLIBANSERIN INVOLVING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2010-11-11 | — | — | WO | claimed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | claimed |
| CN-100343260-C | Cephem compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2007-10-17 | — | — | CN | claimed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | claimed |
| US-5319080-A | Antiviral agents | CIBA-GEIGY CORPORATION (US) | 1994-06-07 | — | — | US | claimed |
| EP-0577558-A2 | Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates | CIBA-GEIGY AG (CH) | 1994-01-05 | — | — | EP | claimed |
| US-5234930-A | Treating psychological, cardiovascular, urogenital and respiratory disorders; diabetes, asthmas, sudden infant death syndrome | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | claimed |
| EP-0542681-A1 | Process for the preparation of carbocyclic nucleosides and its intermediates | CIBA-GEIGY AG (CH) | 1993-05-19 | — | — | EP | claimed |
| EP-0538194-A1 | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | claimed |
| EP-0160252-B1 | Antibacterial compounds | Takeda Chemical Industries, Ltd. (JP) | 1992-08-26 | — | — | EP | claimed |
| EP-0354297-B1 | THIADIAZINES, PROCESS FOR PRODUCTION THEREOF, AND INSECTICIDAL AND ACARICIDAL AGENTS COMPRISING THE THIADIAZINES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-08-05 | — | — | EP | claimed |
| US-4788185-A | Cephalosporin compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-11-29 | — | — | US | claimed |
| US-3991042-A | Basic azo dyestuffs containing a benzthiazole and a tetrahydroquinoline nucleus | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-09 | — | — | US | claimed |
| US-3948877-A | POLYACRYLONITRILE, ACID MODIFIED POLYESTERS OR POLYAMIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225585-A1 | PYRAZOLE AMIDE COMPOUNDS AND USES THEREOF | BROX, OAT, CAT | HSD17B10 3321/4885MEN1 2649/4885KMT2A 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.